Following the experimental evidence unveiling the important roles of PRSS3, PAR2, and FOSL1 in promoting cancer metastasis, we first investigated their clinical significance using the Kaplan–Meier plotter.[44] The Kaplan–Meier plots revealed that high levels of PRSS3 and FOSL1 were linked with both shorter overall survival (OS) and post‐progression survival (PPS) of NSCLC patients, while more PAR2 only resulted in lower OS. The gene discussed is FOSL1; the disease is cancer.